Kancera To Pursue Ex-AZ Asset Targeting Fractalkine Into Clinic

 
• By Sukaina Virji

Swedish drug developer Kancera has exercised an exclusive option to develop a former AstraZeneca drug candidate. The small molecule shares a mechanism of action with a clinical-stage therapeutic antibody from Eisai.

Homeless dog
Abandoned by AstraZeneca, fractalkine project gets new lease of life • Source: Shutterstock

More from R&D

More from Scrip